Download PDF
Arthritis und Rheuma 2023; 43(06): 403-409
DOI: 10.1055/a-2197-9610
Schwerpunkt

Uveitis bei juveniler idiopathischer Arthritis

Leitliniengerechtes Management und therapierefraktäre Verläufe
Arnd Heiligenhaus
1   FEBO
2   Augenzentrum am St. Franziskus Hospital, Münster, Deutschland
3   Universitätsklinikum Duisburg-Essen, Essen, Deutschland
,
Karoline Baquet-Walscheid
1   FEBO
2   Augenzentrum am St. Franziskus Hospital, Münster, Deutschland
3   Universitätsklinikum Duisburg-Essen, Essen, Deutschland
,
Christoph Tappeiner
1   FEBO
4   Pallas Klinik, Olten, Schweiz
5   Klinik für Augenheilkunde, Universitätsklinikum Duisburg-Essen, Essen, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Darstellung der aktualisierten deutschsprachigen interdisziplinären Leitlinie zur Diagnostik und Therapie der juvenilen idiopathischen Arthritis (JIA)-assoziierten Uveitis. Nach JIA-Erstdiagnose sollten zeitnah regelmäßige augenärztliche Kontrollen erfolgen mit dem Ziel, die Uveitis vor Manifestation irreversibler Folgeschäden zu diagnostizieren. Zur antientzündlichen Therapie finden aktuell Kortikosteroide, konventionell synthetische (cs), biologische (b) und andere Disease-Modifying Antirheumatic Drugs (DMARD) Verwendung. Eine enge Kooperation durch einen mit der JIA-assoziierten Uveitis und ihrer Behandlung erfahrenen Augenarzt und einen Kinder- und Jugendrheumatologen sollte gewährleistet werden. Frühzeitige Diagnose und aktuelle leitliniengerechte Therapie können die Langzeitprognose der JIA-assoziierten Uveitis wesentlich verbessern. Ausgewählte Kasuistiken illustrieren das therapeutische Management bei therapierefraktärem Krankheitsverlauf.

Schlüsselwörter

Juvenile idiopathische Arthritis - Diagnostik - Therapie - Uveitis


Publication History

Article published online:
19 June 2024

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Heiligenhaus A, Niewerth M, Ganser G. et al Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46: 1015-1019 DOI: 10.1093/rheumatology/kem053.
    CrossrefPubMedGoogle Scholar
  • 2 Kotaniemi K, Kautiainen H, Karma A. et al Occurrence of uveitis in recently diagnosed juvenile chronic arthritis. A prospective study. Ophthalmology 2001; 108: 2071-2075 DOI: 10.1016/s0161-6420(01)00773-4.
    CrossrefPubMedGoogle Scholar
  • 3 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516 DOI: 10.1016/j.ajo.2005.03.057.
    CrossrefPubMedGoogle Scholar
  • 4 Walscheid K, Glandorf K, Rothaus K. et al Enthesitis-related arthritis: prevalence and complications of associated uveitis in children and adolescents from a population-based nationwide study in Germany. J Rheumatol 2021; 48: 262-269 DOI: 10.3899/jrheum.191085.
    CrossrefPubMedGoogle Scholar
  • 5 De Boer J, Steijaert A, van den Bor R. et al Development of macular edema and impact and visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm 2015; 23: 67-73 DOI: 10.3109/09273948.2013.871566.
    CrossrefPubMedGoogle Scholar
  • 6 Böhm MR, Tappeiner C, Breitbach MA. et al Ocular hypotony in patients with juvenile idiopathic arthritis-associated uveitis. Am J Ophthalmol 2017; 173: 45-55 DOI: 10.1016/j.ajo.2016.09.018.
    CrossrefPubMedGoogle Scholar
  • 7 Thorne JE, Woreta FA, Dunn JP. et al Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117: 1436-1441 DOI: 10.1016/j.ophtha.2009.12.003.
    CrossrefPubMedGoogle Scholar
  • 8 Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm 2013; 21: 478-485 DOI: 10.3109/09273948.2013.815785.
    CrossrefPubMedGoogle Scholar
  • 9 De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003; 87: 879-884 DOI: 10.1136/bjo.87.7.879.
    CrossrefPubMedGoogle Scholar
  • 10 Heiligenhaus A, Klotsche J, Niewerth M. et al Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. Arthritis Res Ther 2020; 22: 81 DOI: 10.1186/s13075-020-02166-3.
    CrossrefPubMedGoogle Scholar
  • 11 Kothari S, Foster CS, Pistilli M. et al The risk of intraocular pressure elevation in pediatric non-infectious uveitis. Ophthalmology 2015; 122: 1987-2001 DOI: 10.1016/j.ophtha.2015.06.041.
    CrossrefPubMedGoogle Scholar
  • 12 Tappeiner C, Klotsche J, Schenck S. et al Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis: data from a cross-sectional analysis of a prospective nationwide study. Clin Exp Rheumatol 2015; 33: 936-944
    PubMedGoogle Scholar
  • 13 Kostik MM, Gaidar EV, Hynnes AY. et al Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol 2016; 34: 714-718
    PubMedGoogle Scholar
  • 14 Papadopoulou C, Kostik M, Böhm M. et al Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr 2013; 163: 879-884 DOI: 10.1016/j.jpeds.2013.03.047.
    CrossrefPubMedGoogle Scholar
  • 15 Tappeiner C, Schenck S, Niewerth M. et al Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care Res 2016; 68: 46-54 DOI: 10.1002/acr.22649.
    CrossrefPubMedGoogle Scholar
  • 16 Lerman MA, Burnham JM, Chang PY. et al Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol 2013; 40: 1394-1403 DOI: 10.3899/jrheum.121180.
    CrossrefPubMedGoogle Scholar
  • 17 Acharya N, Patel S, Homayounfar G. et al Relapse of juvenile idiopathic arthritis associated uveitis after discontinuation of immunomodulatory therapy. Ocul Immunol Inflamm 2019; 27: 686-692 DOI: 10.1080/09273948.2018.1424341.
    CrossrefPubMedGoogle Scholar
  • 18 Lerman MA, Lewen MD, Kempen JH, Mills MD. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 2015; 160: 193-200 DOI: 10.1016/j.ajo.2015.04.016.
    CrossrefPubMedGoogle Scholar
  • 19 Horton S, Jones AP, Guly CM. et al Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial. Am J Ophthalmol 2019; 207: 170-179 DOI: 10.1016/j.ajo.2019.06.007.
    CrossrefPubMedGoogle Scholar
  • 20 Ramanan AV, Dick AD, Jones AP. et al Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017; 376: 1637-1646 DOI: 10.1056/NEJMoa1614160.
    CrossrefPubMedGoogle Scholar
  • 21 Simonini G, Druce K, Cimaz R. et al Current evidence of anti-tumor necrosis factor a treatment efficacy in childhood chronic uveitis: a systemic review and meta-analysis approach of individual drugs. Arthritis Care Res 2014; 66: 1073-1084 DOI: 10.1002/acr.22214.
    CrossrefPubMedGoogle Scholar
  • 22 Saurenmann RK, Levin AV, Feldman BM. et al Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF alpha agents. J Pediatr 2006; 149: 833-836 DOI: 10.1016/j.jpeds.2006.08.044.
    CrossrefPubMedGoogle Scholar
  • 23 Calvo-Rio V, Santos-Gomez M, Calvo I. et al Anti-IL-6R tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-TNF therapy. A multicenter study of 25 patients. Arthritis Rheumatol 2016; 69: 668-675 DOI: 10.1002/art.39940.
    CrossrefPubMedGoogle Scholar
  • 24 Tappeiner C, Mesquida M, Adan A. et al Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2016; 43: 2183-2188 DOI: 10.3899/jrheum.160231.
    CrossrefPubMedGoogle Scholar
  • 25 Ramanan AV, Dick AD, Guly C. et al Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol 2020; 02: e135-e141 DOI: 10.1016/S2665-9913(20)30008-4.
    CrossrefPubMedGoogle Scholar
  • 26 Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis – a case report. J Rheumatol 2008; 35: 1897-1898
    Google Scholar
  • 27 Tappeiner C, Miserocchi E, Bodaghi B. et al Abatacept in the treatment of severe, longstanding and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015; 42: 706-711 DOI: 10.3899/jrheum.140410.
    CrossrefPubMedGoogle Scholar
  • 28 Ruperto N, Brunner HI, Synoverska O. et al Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 2021; 398: 1984-1996 DOI: 10.1016/S0140-6736(21)01255-1.
    CrossrefPubMedGoogle Scholar
  • 29 Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocular Immunol Inflamm 2019; 27: 1232-1234 DOI: 10.1080/09273948.2019.1605453.
    CrossrefPubMedGoogle Scholar
  • 30 Miserocchi E, Giuffre C, Cornalba M. et al JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 2020; 39: 847-851 DOI: 10.1007/s10067-019-04875-w.
    CrossrefPubMedGoogle Scholar
  • 31 Baquet-Walscheid K, Heinz C, Rath T. et al Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: a case report. Ocul Immunol Inflamm 2023; 31: 1079-1080 DOI: 10.1080/09273948.2022.2069128.
    CrossrefPubMedGoogle Scholar
  • 32 Ramanan AV, Guly CM, Keller SY. et al Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials 2021; 22: 689 DOI: 10.1186/s13063-021-05651-5.
    CrossrefPubMedGoogle Scholar
  • 33 Heiligenhaus A, Miserocchi E, Heinz C. et al Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011; 50: 1390-1394 DOI: 10.1093/rheumatology/ker107.
    CrossrefPubMedGoogle Scholar
  • 34 Miserocchi E, Pontikaki I, Modorati G. et al Rituximab for uveitis. Ophthalmology 2011; 118: 223-224 DOI: 10.1016/j.ophtha.2010.07.031.
    CrossrefPubMedGoogle Scholar
  • 35 Miserocchi E, Modorati G, Berchicci L. et al Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 2016; 100: 782-786 DOI: 10.1136/bjophthalmol-2015-306790.
    CrossrefPubMedGoogle Scholar
  • 36 Baquet-Walscheid K, Wildschütz L, Kasper M. et al Assessment of angiogenesis-related parameters in juvenile idiopathic arthritis-associated uveitis. Mol Biol Rep 2022; 49: 6093-6102 DOI: 10.1007/s11033-022-07398-x.
    CrossrefPubMedGoogle Scholar
  • 37 Ayuso VK, van de Winkel EL, Rothova A. et al Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151: 217-222 DOI: 10.1016/j.ajo.2010.08.021.
    CrossrefPubMedGoogle Scholar